Announcements Trials

Browse Landscape

Status

Sponsor Class

Study Type

Observational 1

Sponsor

Cancer Type

NET 1 Endocrine 1

Conditions

Neoplasms 41 Breast Neoplasms 40 Lung Neoplasms 25 Carcinoma, Non-Small-Cell Lung 20 Colorectal Neoplasms 19 Uterine Cervical Neoplasms 13 Prostatic Neoplasms 13 Head and Neck Neoplasms 11 Carcinoma, Hepatocellular 11 Pancreatic Neoplasms 10 Melanoma 10 Ovarian Neoplasms 9 Neoplastic Cells, Circulating 7 Myelodysplastic Syndromes 7 Glioma 7 Esophageal Neoplasms 7 Endometrial Neoplasms 7 Brain Neoplasms 7 Sarcoma 6 Multiple Myeloma 6 Gastrointestinal Neoplasms 6 Carcinoma, Renal Cell 6 Triple Negative Breast Neoplasms 5 Neoplasm Metastasis 5 Leukemia, Myeloid, Acute 5 Disease 5 Colonic Neoplasms 5 Uveal Melanoma 4 Skin Neoplasms 4 Neoplasm, Residual 4

Interventions

lutetium Lu 177 dotatate 20 Magnetic Resonance Spectroscopy 10 pembrolizumab 9 Specimen Handling 7 Everolimus 7 cabozantinib 6 Nivolumab 6 lenvatinib 5 177Lu-octreotide, DOTA(0)-Tyr(3)- 5 surufatinib 4 amino-acid, glucose, and electrolyte solution 4 Capecitabine 4 olaparib 3 lanreotide 3 atezolizumab 3 Temozolomide 3 Octreotide 3 Lutetium-177 3 Ipilimumab 3 Injections 3 Fluorodeoxyglucose F18 3 Cyclophosphamide 3 gallium Ga 68 dotatate 2 fludarabine phosphate 2 fludarabine 2 avelumab 2 X-Rays 2 Radiotherapy 2 Phantoms, Imaging 2 PM 01183 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Neuroendocrine Tumors × Blood Specimen Collection × 1 year × Clear all

NCT06430021 2026-05-22

PRO-NEM1

Centre Hospitalier Universitaire Dijon

Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon ⚡